Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(14 years from now) | |
US11617793 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
US11510984 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
US11291728 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Sep 20, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 20, 2029 |
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(6 years from now) | |
US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
US8496973 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Mar, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) |
Market Authorisation Date: 14 February, 2012
Treatment: Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning tha...
Dosage: SOLUTION;INTRAVENOUS